0.0252USD0.00%Mkt Cap: —P/E: —Last update: 2026-05-29
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assess…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)16.57K USD
Gross Profit16.57K USD
Net Income (TTM)-6.50M USD
Revenue/Share0.0080 USD
Last Price0.0252 USD
Fiscal Year End—
MR Quarter—
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.00
EPS (TTM)—
EPS (Forward)—
52W Range
0.011660% of range0.0341
52W High0.0341 USD
52W Low0.0116 USD
Profitability
Gross Margin100.00%
Oper. Margin-66598.40%
EBITDA Margin0.00%
Profit Margin-43832.49%
ROE-93.19%
ROA-83.67%
Growth
Revenue Growth185.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.73M USD
CapEx (TTM)419.31K USD
FCF Margin-23708.10%
FCF Yield—
Net Debt-6.54M USD
Net Debt/EBITDA1.04
Balance Sheet
Debt/Equity0.10
Current Ratio15.76
Quick Ratio14.41
Book Value/Sh3.008 USD
Cash/Share2.391 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float2.83M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta2.26
S&P 52W Chg27.94%
Avg Vol (30d)194
Avg Vol (10d)—
Technical Indicators
RSI (14)8.6
MACD-0.0028
MACD Signal-0.0014
MACD Hist.-0.0014
BB Upper0.0328 USD
BB Middle0.0227 USD
BB Lower0.0126 USD
BB Width88.85%
ATR (14)0.0009 USD
Vol Ratio (20d)0.38x